The Carbonic Anhydrase IX inhibitor SLC-0111 as emerging agent against the mesenchymal stem cell-derived pro-survival effects on melanoma cells

References

• Whiteside T. The tumor microenvironment and its role in promoting tumor growth. Oncogene 2008;27:5904–12.
   PubMed Web of Science ®Google Scholar
• Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med 2013;19:1423–37.
   PubMed Web of Science ®Google Scholar
• Werb Z, Lu P. The role of stroma in tumor development. Cancer J 2015;21:250–3.
   PubMed Web of Science ®Google Scholar
• Fouad YA, Aanei C. Revisiting the hallmarks of cancer. Am J Cancer Res 2017; 7:1016–36.
   PubMed Web of Science ®Google Scholar
• Cirri P, Chiarugi P. Cancer associated fibroblasts: the dark side of the coin. Am J Cancer Res 2011;1:482–97.
   PubMed Web of Science ®Google Scholar
• Dvorak HF. Tumors: wounds that do not heal-redux. Cancer Immunol Res 2015;3:1–11.
   PubMed Web of Science ®Google Scholar
• Giannoni E, Bianchini F, Masieri L, et al. Reciprocal activation of prostate cancer cells and cancer-associated fibroblasts stimulates epithelial-mesenchymal transition and cancer stemness. Cancer Res 2010;70:6945–56.
   PubMed Web of Science ®Google Scholar
• Hall B, Andreeff M, Marini F. The participation of mesenchymal stem cells in tumor stroma formation and their application as targeted-gene delivery vehicles. Handb Exp Pharmacol 2007;180:263–83.
   Google Scholar
• Barcellos-de-Souza P, Comito G, Pons-Segura C, et al. Mesenchymal stem cells are recruited and activated into carcinoma-associated fibroblasts by prostate cancer microenvironment-derived TGF-β1. Stem Cells 2016;34:2536–47.
   PubMed Web of Science ®Google Scholar
• Lazennec G, Lam PY. Recent discoveries concerning the tumor – mesenchymal stem cell interactions. Biochim Biophys Acta 2016;1866:290–9.
   PubMed Web of Science ®Google Scholar
• Laurenzana A, Biagioni A, Bianchini F, et al. Inhibition of uPAR-TGFβ crosstalk blocks MSC-dependent EMT in melanoma cells. J Mol Med (Berl) 2015;93:783–94.
   PubMed Web of Science ®Google Scholar
• Peppicelli S, Bianchini F, Toti A, et al. Extracellular acidity strengthens mesenchymal stem cells to promote melanoma progression. Cell Cycle 2015;14:3088–100.
   PubMed Web of Science ®Google Scholar
• (a) Supuran CT. Carbonic anhydrase inhibitors as emerging agents for the treatment and imaging of hypoxic tumors. Expert Opin Investig Drugs 2018; 27:963–70.
   PubMed Web of Science ®Google Scholar
  (b) Nocentini A, Supuran CT. Carbonic anhydrase inhibitors as antitumor/antimetastatic agents: a patent review (2008-2018). Expert Opin Ther Pat 2018; 28:729–40.
   PubMed Web of Science ®Google Scholar
• (a) Supuran CT, Carbonic anhydrase inhibition and the management of hypoxic tumors. Metabolites 2017;7:E48.
   PubMed Web of Science ®Google Scholar
  (b) Supuran CT, Alterio V, Di Fiore A, et al. Inhibition of carbonic anhydrase IX targets primary tumors, metastases, and cancer stem cells: three for the price of one. Med Res Rev 2018; 38:1799–836.
   PubMed Web of Science ®Google Scholar
• Pastorekova S, Gillies RJ. The role of carbonic anhydrase IX in cancer development: links to hypoxia, acidosis, and beyond. Cancer Metastasis Rev 2019;38:65–77.
   PubMed Web of Science ®Google Scholar
• Ihnatko R, Kubes M, Takacova M, et al. Extracellular acidosis elevates carbonic anhydrase IX in human glioblastoma cells via transcriptional modulation that does not depend on hypoxia. Int J Oncol 2006;29:1025–33.
   PubMed Web of Science ®Google Scholar
• Robertson N, Potter C, Harris AL. Role of carbonic anhydrase IX in human tumor cell growth, survival, and invasion. Cancer Res 2004;64:6160–5.
   PubMed Web of Science ®Google Scholar
• Andreucci E, Peppicelli S, Carta F, et al. Carbonic anhydrase IX inhibition affects viability of cancer cells adapted to extracellular acidosis. J Mol Med (Berl) 2017;95:1341–53.
   PubMed Web of Science ®Google Scholar
• Peppicelli S, Bianchini F, Calorini L. Extracellular acidity, a “reappreciated” trait of tumor environment driving malignancy: perspectives in diagnosis and therapy. Cancer Metastasis Rev 2014; 33:823–32.
   PubMed Web of Science ®Google Scholar
• Peppicelli S, Bianchini F, Torre E, Calorini L. Contribution of acidic melanoma cells undergoing epithelial-to-mesenchymal transition to aggressiveness of non-acidic melanoma cells. Clin Exp Metastasis 2014;31:423–33.
   PubMed Web of Science ®Google Scholar
• Chen TR. In situ detection of mycoplasma contamination in cell cultures by fluorescent Hoechst 33258 stain. Exp Cell Res 1977; 104:255–62.
   PubMed Web of Science ®Google Scholar
• Ruzzolini J, Peppicelli S, Andreucci E, et al. Everolimus selectively targets vemurafenib resistant BRAF(V600E) melanoma cells adapted to low pH. Cancer Lett 2017;408:43–54.
   PubMed Web of Science ®Google Scholar
• Livak KJ, Schmittgen TD. Analysis of relative gene expression datausing real-time quantitative PCR and the 2 [-Delta Delta C(T)] Method. Methods 2001; 25:402–8.
   PubMed Web of Science ®Google Scholar
• Peppicelli S, Ruzzolini J, Bianchini F, et al. Anoikis resistance as a further trait of acidic-adapted melanoma cells. J Oncol 2019;2019:8340926.
   PubMed Web of Science ®Google Scholar
• Nazarian R, Shi H, Wang Q, et al. Melanomas acquire resistance to BRAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 2010;468:973–7.
   PubMed Web of Science ®Google Scholar
• Atefi M, von Euw E, Attar N, et al. Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway. PLoS One 2011;6:e28973.
   PubMed Web of Science ®Google Scholar
• Maheswaran S, Settleman J, Wargo JA, et al. TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF-mutant melanoma. Sci Transl Med 2013;5:196–8.
   Web of Science ®Google Scholar
• Karp JM, Leng Teo GS. Mesenchymal stem cell homing: the devil is in the details. Cell Stem Cell 2009;4:206–16.
   PubMed Web of Science ®Google Scholar
• Karnoub AE, Dash AB, Vo AP, et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 2007;449:557–63.
   PubMed Web of Science ®Google Scholar
• (a) Lou Y, McDonald PC, Oloumi A, et al. Targeting tumor hypoxia: suppression of breast tumor growth and metastasis by novel carbonic anhydrase IX inhibitors. Cancer Res 2011; 71:7, 3364–76.
   PubMed Web of Science ®Google Scholar
  (b) Pacchiano F, Carta F, McDonald PC, et al. Ureido-substituted benzenesulfonamides potently inhibit carbonic anhydrase IX and show antimetastatic activity in a model of breast cancer metastasis. J Med Chem 2011;54:1896–902.
   PubMed Web of Science ®Google Scholar
• McDonald PC, Dedhar S. Carbonic anhydrase IX (CAIX) as a mediator of hypoxia-induced stress response in cancer cells. Subcell Biochem 2014;75:255–69.
   PubMedGoogle Scholar
• Bozdag M, Carta F, Ceruso M, et al. Discovery of 4- hydroxy-3-(3-(phenylureido)benzenesulfonamides as SLC- 0111 analogues for the treatment of hypoxic tumors overex- pressing carbonic anhydrase IX. J Med Chem 2018;61:6328–38.
   PubMed Web of Science ®Google Scholar
• Supuran CT. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat Rev Drug Discov 2008;7:168–81.
   PubMed Web of Science ®Google Scholar
• Paoli P, Giannoni E, Chiarugi P. Anoikis molecular pathways and its role in cancer progression. Biochim Biophys Acta 2013;1833:3481–98.
   PubMed Web of Science ®Google Scholar
• Chafe SC, Lou Y, Sceneay J, et al. Carbonic anhydrase IX promotes myeloid-derived suppressor cell mobilization and establishment of a metastatic niche by stimulating G-CSF production. Cancer Res 2015;75:996–1008.
   PubMed Web of Science ®Google Scholar
• Alonso SR, Tracey L, Ortiz P, et al. A high-throughput study in melanoma identifies epithelial-mesenchymal transition as a major determinant of metastasis. Cancer Res 2007;67:3450–60.
   PubMed Web of Science ®Google Scholar
• Caramel J, Papadogeorgakis E, Hill L, et al. A switch in the expression of embryonic EMT-inducers drives the development of malignant melanoma. Cancer Cell 2013;24:466–80.
   PubMed Web of Science ®Google Scholar
• Shin HJ, Rho SB, Jung DC, et al. Carbonic anhydrase IX (CA9) modulates tumor-associated cell migration and invasion. J Cell Sci 2011;124:1077–87.
   PubMed Web of Science ®Google Scholar
• Voon DC, Wang H, Koo JK, et al. EMT-induced stemness and tumorigenicity are fueled by the EGFR/Ras pathway. PLoS One 2013;8:e70427.
   PubMed Web of Science ®Google Scholar
• Swietach P, Wigfield S, Cobden P, et al. Tumor-associated carbonic anhydrase 9 spatially coordinates intracellular pH in three-dimensional multicellular growths. J Biol Chem 2008;283:20473–83.
   PubMed Web of Science ®Google Scholar
• Ledaki I, McIntyre A, Wigfield S, et al. Carbonic anhydrase IX induction defines a heterogeneous cancer cell response to hypoxia and mediates stem cell-like properties and sensitivity to HDAC inhibition. Oncotarget 2015; 6:19413–27.
   PubMedGoogle Scholar
• Girotti MR, Marais RD. Vu: EGF receptors drive resistance to BRAF inhibitors. Cancer Discov 2013;3:487–90.
   PubMed Web of Science ®Google Scholar
• Prahallad A, Sun C, Huang S, et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 2012;483:100–3.
   PubMed Web of Science ®Google Scholar
• Sabbatino F, Wang Y, Wang X, et al. PDGFRαup-regulation mediated by sonic hedgehog pathway activation leads to braf inhibitor resistance in melanoma cells with BRAF mutation. Oncotarget 2014;5:1926–41.
   PubMedGoogle Scholar
• Rossi A, Roberto M, Panebianco M, et al. Drug resistance of BRAF-mutant melanoma: review of up-to-date mechanisms of action and promising targeted agents. Eur J Pharmacol 2019;862:172621.
   PubMed Web of Science ®Google Scholar
• Federici C, Lugini L, Marino ML, et al. Lansoprazole and carbonic anhydrase IX inhibitors sinergize against human melanoma cells. J Enzyme Inhib Med Chem 2016;31:119–25.
   PubMed Web of Science ®Google Scholar
• Faes S, Planche A, Uldry E, et al. Targeting carbonic anhydrase IX improves the anti-cancer efficacy of mTOR inhibitors. Oncotarget 2016;7:36666–80.
   PubMedGoogle Scholar
• McDonald PC, Chia S, Bedard PL, et al. A Phase 1 Study of SLC-0111, a Novel Inhibitor of Carbonic Anhydrase IX, in patients with advanced solid tumors. Am J Clin Oncol 2020; in press (accepted for publication). DOI:10.1097/COC.0000000000000691
   Web of Science ®Google Scholar
• Available from: https://clinicaltrials.gov/ct2/show/NCT03450018 (last accessed April 1, 2020).
   Google Scholar